TERMS OF PARTICIPATION

Below you will find all the information you need if you are interested in participating in the 2024 Medical Award in ASMD and Pompe Disease. Your participation in the 2024 Medical Award Program will be governed by these Terms of Participation.

Sanofi has the right to change the Terms of Participation any time for any reason and without further notice. It is therefore recommended that you check these Terms of Participation on a regular basis.

1. What is the objective of the 2024 Medical Award in ASMD and Pompe Disease?

The objective is to encourage discussion and support sharing of clinical cases and experience in ASMD and Pompe disease in order to increase knowledge of both diseases within the broader medical community.

Up to 10 of the highest-scoring applications will be selected to receive a Medical Award. See the "Selection" tab for more information.

2. What does the 2024 Medical Award in ASMD and Pompe Disease consist of?

Sanofi will provide in-kind support to the winning applicants. The in-kind support will consist of:

• Presentation and discussion of clinical cases with the relevant Scientific Committee in order to receive further guidance on patient management and publication preparation
• Medical writing/editorial support for potential to publish these clinical cases/case series
• The opportunity to network with other applicants with similar cases, for potential collaboration opportunities

In addition, winners will have the opportunity to present their work at congresses, as well as Sanofi-organized events in the future. Their presentations may be used for educational purposes by Sanofi, if additional permission for that has been provided.

Medical writing and editorial support will be provided by GK Pharmacomm.

The 2024 Medical Award in ASMD and Pompe Disease is subject to fulfilment of the conditions specified under point 7 below.

3. Which types of clinical data and experience are eligible for submission for a 2024 Medical Award in ASMD?

The abstracts of cases/case series on ASMD providing insights into any of the following topics are eligible for submission for a Medical Award in ASMD:

• Clinical manifestations
• Natural history
• Novel diagnostic or monitoring approaches including biomarkers
• Diagnostic challenges (including missed or delayed diagnosis, (sub)population screening)
• Genotype phenotype correlation
• Novel variants
• Patient stratification
• Disease management (including transplantation and treatment)
• Patient Reported Outcomes (PROs)

4. Which types of clinical data and experience are eligible for submission for a 2024 Medical Award in Pompe Disease?

The abstracts of cases/case series on Pompe disease providing insights into any of the following topics are eligible for submission for a Medical Award:

• Clinical manifestations (submissions describing unusual manifestations are encouraged)
• Natural history
• Novel diagnostic or monitoring approaches including biomarkers
• Diagnostic challenges (including missed or delayed diagnosis)
• Genotype phenotype correlation
• Novel variants
• Disease management (including treatment)
• Interface between clinical management and public health issues (e.g., continuing medical education, primary care units, screening)
• Patient Reported Outcomes (PROs)

5. Who can apply for a 2024 Medical Award in ASMD and Pompe Disease?

Only individuals residing and working in the following countries can apply for a Medical Award in ASMD: Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, Colombia, Czech Republic, Denmark, Egypt, Finland, Germany, Greece, Hungary, Iceland, India, Iraq, Israel, Italy, Japan, Kuwait, Mexico, Morocco, The Netherlands, Norway, Oman, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Taiwan, Tunisia, Ukraine,  the United Arab Emirates, United States of America.

For Pompe disease, submissions from China will also be eligible.

Junior clinicians are encouraged to apply. See the “Requirements” tab for more information.

6. How can you submit a proposal for a 2024 Medical Award?

Applications can be emailed to MedicalAward@gkpharmacomm.co.uk.

See the “Application Process” tab for more information.

7. What is the deadline for applications for a 2024 Medical Award?

You have until the 30th of June 2024 to submit your application. See the “Application Process” tab for more information. Any costs in relation to the 2024 Medical Award application will be borne by the applicant.

8. Who will select the winners?

All qualifying Medical Award applications will be evaluated by the relevant Scientific Committee, who will select the winning application against predefined criteria. For more information, see the “Selection” and “Scientific Committees” tabs. The decision of the Scientific Committee is final. There will be no further correspondence on the method of selection or the outcome of the selection process.

The winning applicants will each receive medical writing and editorial support provided by GK Pharmacomm, provided that the following conditions are met:

• Patient consent needs to be secured and proof of this may be requested
• Each applicant and their institution must undergo, and successfully pass, a Sanofi-led due diligence process
• The winning applicant's institution must enter into a written agreement with Sanofi, in accordance with applicable laws and regulations and Sanofi corporate policies and standards

Important: In cases where the above conditions are not met, the applicant will not receive a Medical Award, in which case the Medical Award may be provided to another applicant to be selected by the Scientific Committee. The same applies in cases where applicable laws and regulations would prohibit Sanofi from providing a Medical Award to an applicant.

9. When will the winners be announced?

The winners will be publicly announced after completion of the due diligence process referred to above in point 7. This announcement is expected to happen in Q4 2024.

10. When will the Medical Award be granted?

The 2024 Medical Award will be granted soon after the written agreement referred to above in point 8 has been signed.

11. What is the extent of the Medical Award?

A 2024 Medical Award is a one-time award. It is granted for the submitted and selected application (case/case series) and cannot be exchanged for another case/case series or another type of publication.

12. What else do you need to know?

Intellectual property & publicity: Intellectual property rights in relation to the application and publication remain with the applicant who has submitted the application for the 2024 Medical Award in ASMD and Pompe Disease. Sanofi and GK Pharmacomm have a perpetual and worldwide right to use, store, and give publicity to all submitted and winning applications for purposes related to the Medical Award. Such publicity may include publication on the internet and at conferences and seminars but is not limited thereto.

Expectations for the winning applicants: Once all requirements referred to above in point 8 have been met and there has been a public announcement of the winners, each winner will be contacted by GK Pharmacomm and will provide materials needed to prepare the abstract/manuscript. The winners will collaborate with GK Pharmacomm and provide their input, reviews, and approval of the abstract/manuscript in reasonable timeframes.

Data protection: Please read the Privacy Policy that explains Sanofi's policies and practices regarding the processing of personal data that applicants provide in connection with their participation in the 2024 Medical Award in ASMD and Pompe Disease and the application process.

Limitation of liability: Sanofi, GK Pharmacomm, and the Scientific Committees will not be liable for any damages of applicants resulting from participation in the 2024 Medical Award in ASMD and Pompe Disease and the application process.

Other: Sanofi decides on all matters not covered by these Terms of Participation. Sanofi may unilaterally terminate the 2024 Medical Award in ASMD and Pompe Disease and the application process at any time for any reason.

The applicant is solely and exclusively responsible for obtaining all required patient permissions and consents for use in patient case presentations, publications, abstracts or in connection with their applications. The applicant is similarly responsible for ensuring compliance with all applicable laws governing the content contained in application submissions, publications and presentations, including, but not limited to, all laws and regulations governing patient privacy and the physician/patient relationship.  Sanofi is not responsible for ensuring compliance with such laws and regulations, and expressly disclaims any potential legal liability related to such compliance.
 
The 2024 Medical Award in ASMD and Pompe Disease is not intended to influence the independent medical judgment or decision-making of any applicant or award winner.  The 2024 Medical Award in ASMD and Pompe Disease does not constitute an inducement of any kind under the US Anti Kickback Statute, 42 U.S.C. § 1320a7b(b) or any other similar law or regulation in any jurisdiction.

Governing law and disputes: These Terms of Participation and your participation in the 2024 Medical Award in ASMD and Pompe Disease and the application process are governed by Massachusetts law. Disputes in relation to the 2024 Medical Award in ASMD and Pompe Disease and/or these Terms of Participation shall be exclusively brought under the jurisdiction of such courts.